Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Clinical Trials

All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2025-05-04

Last Posted Date: 2025-05-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 21

Registration Number: NCT06956170

Locations: 🇯🇵
GSK Investigational Site, Hokkaido, Japan
🇯🇵
GSK Investigation Site, Fukushima City, Fukushima-Ken, Japan

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Phase 3

Not yet recruiting

Conditions: Multiple Myeloma, Newly Diagnosed

Interventions: Drug: Lenalidomide (Revlimid®)
Drug: Elranatamab
Drug: Daratumumab SC (Darzalex)
Procedure: Autologous Stem Cell Transplantation
Drug: Bortezomib (Velcade®)
Drug: Dexamethasone

First Posted Date: 2025-04-09

Last Posted Date: 2025-05-20

Lead Sponsor: Intergroupe Francophone du Myelome

Target Recruit Count: 824

Registration Number: NCT06918002

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Phase 1

Recruiting

Conditions: Metastatic Breast Cancer
Recurrent Breast Cancer

Interventions: Drug: Bortezomib (B)
Drug: Cisplatin (CDDP)

First Posted Date: 2025-03-28

Last Posted Date: 2025-04-02

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 20

Registration Number: NCT06900647

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China

China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Daratumumab
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2025-03-11

Last Posted Date: 2025-04-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 72

Registration Number: NCT06868654

Locations: 🇨🇳
GSK Investigational Site, Zhengzhou, China

Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Belantamab mafodotin
Drug: Daratumumab
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2025-03-11

Last Posted Date: 2025-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT06868667

Locations: 🇯🇵
GSK Investigational Site, Yokohama, Japan

Feasibility of Using Bortezomib with or Without Chemotherapy in Patients with Atypical Teratoid/rhabdoid Tumors

Phase 2

Active, not recruiting

Conditions: Atypical Teratoid/rhabdoid Tumors (AT/RTs)
Central Nervous System (CNS) Tumors

Interventions: Drug: Bortezomib

First Posted Date: 2025-02-28

Last Posted Date: 2025-02-28

Lead Sponsor: Taipei Medical University

Target Recruit Count: 6

Registration Number: NCT06853080

Locations: 🇨🇳
Taipei Medical University Hospital, Taipei, Taiwan

A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

Phase 2

Not yet recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Glofitamab
Drug: Bortezomib
Drug: Orelabrutinib

First Posted Date: 2024-10-24

Last Posted Date: 2024-11-19

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 29

Registration Number: NCT06656221

Rapid DFLC Response Predict CHR in AL Amyloidosis

Recruiting

Conditions: Systemic AL Amyloidosis

Interventions: Drug: Dara IV
Drug: Bortezomib (drug)
Drug: Dexamethasone
Drug: Cyclophosphamide (CTX)
Drug: Dara SC

First Posted Date: 2024-10-04

Last Posted Date: 2024-10-30

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 50

Registration Number: NCT06627309

Locations: 🇨🇳
Fuxing Hospital affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cilta-cel
Drug: Talquetamab
Drug: Daratumumab
Drug: Bortezomib
Drug: Teclistamab
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-08-29

Last Posted Date: 2025-04-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 40

Registration Number: NCT06577025

Locations: 🇪🇸
Hosp. Univ. 12 de Octubre, Madrid, Spain
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 9 locations

Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

Phase 1

Recruiting

Conditions: Pancreas Cancer

Interventions: Drug: Bortezomib Injection
Drug: Sintilimab
Drug: mFOLFIRINOX

First Posted Date: 2024-08-27

Last Posted Date: 2025-01-10

Lead Sponsor: Zhejiang University

Target Recruit Count: 63

Registration Number: NCT06572813

Locations: 🇨🇳
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy